Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy.
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: James L. Gulley, David Spigel, Karen Kelly, Jason Claud Chandler, Arun Rajan, Raffit Hassan, Deborah Jean Lee Wong, Joseph Leach, William Jeffery Edenfield, Ding Wang, Nandagopal Vrindavanam, Glen J. Weiss, Jayne S. Gurtler, Hans Juergen Grote, Anja von Heydebreck, Kevin M. Chin, Nicholas Iannotti
Institutions: National Institutes of Health, National Cancer Institute, Sarah Cannon, Tennessee Oncology, UC Davis Comprehensive Cancer Center, Center for Cancer Research, University of California, Los Angeles, Henry Ford Health, Western Regional Medical Center, Merck KGaA, Darmstadt (Germany), EMD Serono, Inc. (United States), Merck Healthcare KGaA, Darmstadt (Germany), Hematology Oncology Associates
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2527615339